Stewart Cooper
Investigator
Dr. Cooper studies molecular and genetic changes underlying liver diseases including hepatitis B and C, and he uses genomic and proteomic approaches to uncover new therapeutic targets for the hepatitis virus. Current research in the Cooper lab includes investigations of how natural killer cells, T cells, and hybrid natural killer T cells may interact to clear hepatitis C, and how related sets of genes influence immune response. Dr. Cooper directs the Kalmanovitz Liver Immunology Laboratory at CPMC, and leads translational research to identify immunological influences on disease outcomes in patients with hepatitis C (including those undergoing liver transplantation). Under Dr. Cooper’s leadership, validated biomarkers for liver and biliary diseases will be used to personalize treatment and help predict an individual’s response to therapy.